PURPOSE: Pulmonary thromboembolism (PTE), is an extremely common medical problem. Yet despite its frequency, much remains to be learned regarding the pathogenic mechanisms that initiate PTE. Marked activation of endothelium, platelets, and leukocytes are key events in thrombogenesis in PTE. Neopterin is produced by monocytes and is a useful biomarker of inflammatory activation. The present study assessed neopterin concentrations as an early biomarker on patients with PTE and healthy people.
METHODS: Serum neopterin concentrations were measured by high performance liquid chromatography (HPLC)in 49 acute pulmonary thromboemboli patients and 30 heathy controls.
RESULTS: Serum neopterin levels of pulmonary emboli and healty group were measured as 18.70±10.60 and 4.80±1.30 nmol/L, respectively. (p< 0.001).
CONCLUSION: There is istatistically significant difference between the pulmonary thrombemboli patients and healthy control.
CLINICAL IMPLICATIONS: Our findings suggest that neopterin levels may have diagnostic value in pulmonary thromboemboli as an early diagnostic marker.There is need more studies in this field.
DISCLOSURE: Arzu Balkan, None.